Jennison Associates
TPST icon

Jennison Associates’s Tempest Therapeutics TPST Stock Holding History

Jennison Associates’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-748
Closed -$3.06M – 699
2017
Q4 		$3.06M Hold
748
– – ﹤0.01% 513
2017
Q3 		$3.11M Sell
748
-1
-0.1% -$4.28K ﹤0.01% 518
2017
Q2 		$3.42M Buy
749
+2
+0.3% +$8.46K ﹤0.01% 517
2017
Q1 		$4.08M Hold
747
– – ﹤0.01% 517
2016
Q4 		$3.34M Sell
747
-266
-26% -$3.31M ﹤0.01% 533
2016
Q3 		$21.2M Sell
1,013
-42
-4% -$760K 0.02% 404
2016
Q2 		$16.1M Sell
1,055
-1
-0.1% -$22.8K 0.02% 426
2016
Q1 		$29.3M Buy
1,056
+205
+24% +$4.33M 0.03% 369
2015
Q4 		$24.3M Sell
851
-286
-25% -$9.43M 0.02% 396
2015
Q3 		$28.2M Sell
1,137
-13
-1% -$875K 0.03% 390
2015
Q2 		$97.3M Buy
1,150
+268
+30% +$24.5M 0.09% 208
2015
Q1 		$89.6M Buy
882
+524
+146% +$69.8M 0.08% 219
2014
Q4 		$46.3M Buy
358
+53
+17% +$3.88M 0.04% 338
2014
Q3 		$14.8M Buy
305
+80
+36% +$2.8M 0.01% 460
2014
Q2 		$6.03M Sell
225
-18
-7% -$424K 0.01% 498
2014
Q1 		$6.36M Buy
+243
New +$6.89M 0.01% 508

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Jennison Associates's TPST Position: Q1 2018 in Review

Jennison Associates sold out of Tempest Therapeutics (TPST) in Q1 2018, closing a stake of 748 shares — an estimated $3.06M sold.

Jennison Associates first reported a position in TPST in Q1 2014 and held it in 16 quarters. The position peaked at $97.3M in Q2 2015. 41 funds tracked by Wall St. Rank hold TPST as of Q1 2018.

  • Jennison Associates reported no remaining Tempest Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Jennison Associates sold 748 Tempest Therapeutics shares in Q1 2018, an estimated $3.06M.
  • Jennison Associates first reported a position in Tempest Therapeutics in Q1 2014 and held it in 16 quarters.
  • Jennison Associates's Tempest Therapeutics position peaked at $97.3M in Q2 2015.
  • 41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2018.

Based on Jennison Associates's 13F filing for Q1 2018, filed 20 Apr 2018.